These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
373 related items for PubMed ID: 8499234
1. [Topical treatment with oxybutynin chloride in neurogenic incontinence]. López Pereira P, Martínez MJ, Muguerza R, Jaureguizar E. Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234 [Abstract] [Full Text] [Related]
9. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. Franco I, Horowitz M, Grady R, Adams RC, de Jong TP, Lindert K, Albrecht D. J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080 [Abstract] [Full Text] [Related]
10. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Haferkamp A, Staehler G, Gerner HJ, Dörsam J. Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396 [Abstract] [Full Text] [Related]
11. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects]. Von Zweigbergk M, Nordin B, Jonsson S. Lakartidningen; 1996 Oct 09; 93(41):3573-6. PubMed ID: 8965514 [No Abstract] [Full Text] [Related]
12. [Value of intravesically instilled oxybutynin in refractory bladder hyperactivity. Study of 15 cases]. Amarenco G, Adba MA, Kerdraon J. Prog Urol; 1992 Oct 09; 2(4):660-3. PubMed ID: 1302108 [Abstract] [Full Text] [Related]
13. Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients. Connor JP, Betrus G, Fleming P, Perlmutter AD, Reitelman C. J Urol; 1994 Apr 09; 151(4):1045-7. PubMed ID: 8126787 [Abstract] [Full Text] [Related]
16. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Kennelly MJ, Lemack GE, Foote JE, Trop CS. Urology; 2009 Oct 09; 74(4):741-5. PubMed ID: 19628264 [Abstract] [Full Text] [Related]
17. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I. Int J Urol; 2004 Aug 09; 11(8):592-6. PubMed ID: 15285747 [Abstract] [Full Text] [Related]
20. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. Di Stasi SM, Giannantoni A, Navarra P, Capelli G, Storti L, Porena M, Stephen RL. J Urol; 2001 Dec 09; 166(6):2232-6. PubMed ID: 11696741 [Abstract] [Full Text] [Related] Page: [Next] [New Search]